Authors' Affiliations: Cancer Science Institute of Singapore, National University of Singapore, Singapore; and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Cancer Res. 2014 Mar 1;74(5):1301-6. doi: 10.1158/0008-5472.CAN-13-3485. Epub 2014 Feb 20.
Adenosine-to-inosine conversion (A-to-I editing), a posttranscriptional modification on RNA, contributes to extensive transcriptome diversity. A-to-I editing is a hydrolytic deamination process, catalyzed by adenosine deAminase acting on double-stranded RNA (ADAR) family of enzymes. ADARs are essential for normal mammalian development, and disturbance in RNA editing has been implicated in various pathologic disorders, including cancer. Thanks to next-generation sequencing, rich databases of transcriptome evolution for cancer development at the resolution of single nucleotide have been generated. Extensive bioinformatic analysis revealed a complex picture of RNA editing change during transformation. Cancer displayed global hypoediting of Alu-repetitive elements with gene-specific editing pattern. In particular, hepatocellular carcinoma editome is severely disrupted and characterized by hyper- and hypoediting of different genes, such as hyperedited AZIN1 (antizyme inhibitor 1) and FLNB (filamin B, β) and hypoedited COPA (coatomer protein complex, subunit α). In hepatocellular carcinoma, not only the recoding editing in exons, but also the editing in noncoding regions (e.g., Alu-repetitive elements and microRNA) displays such complex editing pattern with site-specific editing trend. In this review, we will discuss current research progress on the involvement of abnormal A-to-I editing in cancer development, more specifically on hepatocellular carcinoma.
腺嘌呤到肌苷的转换(A-to-I 编辑)是 RNA 上的一种转录后修饰,有助于广泛的转录组多样性。A-to-I 编辑是一种水解脱氨过程,由双链 RNA(ADAR)家族酶催化的腺苷脱氨酶作用。ADAR 在正常哺乳动物发育中是必不可少的,并且 RNA 编辑的紊乱与各种病理紊乱有关,包括癌症。由于下一代测序技术,已经生成了癌症发展的转录组进化的丰富数据库,分辨率达到单个核苷酸。广泛的生物信息学分析揭示了转化过程中 RNA 编辑变化的复杂情况。癌症显示出 Alu 重复元件的全局低编辑,具有基因特异性的编辑模式。特别是,肝细胞癌的编辑组严重破坏,表现为不同基因的高编辑和低编辑,例如高编辑的 AZIN1(抗酶抑制剂 1)和 FLNB(肌动蛋白,β)和低编辑的 COPA(衣壳蛋白复合物,亚基α)。在肝细胞癌中,不仅外显子中的重编码编辑,而且非编码区域(例如,Alu 重复元件和 microRNA)也显示出这种复杂的编辑模式,具有特定部位的编辑趋势。在这篇综述中,我们将讨论异常 A-to-I 编辑参与癌症发展的研究进展,特别是在肝细胞癌方面。